Backgroud:
Discovering effective immune-related biomarkers is vital to ensure efficient immunotherapy for glioma patients. Integrin Alpha L(ITGAL), essential to inflammatory and immune responses, have not been studied in gliomas, systematically.
Methods
RNA‑seq data and corresponding clinical information of glioma patients were collected from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA), and mRNA data of normal brain tissues were obtained in Genotype-Tissue Expression (GTEx) project. Wilcoxon test was performed to analyze the correlation of ITGAL expression and glioma subtypes. Univariate and multivariate cox proportional hazards regression, receiver operating characteristic (ROC) curves and Kaplan-Meier plots were used to evaluate the prognostic value of ITGAL in glioma. Functional enrichment analyses and immune infiltration analysis were performed to investigate the potential function in mediating the immune response in the tumor microenvironment. Finally, we evaluated the ability of ITGAL for predicting the efficacy of ICB treatment for patients.
Results
We found the up-regulation of ITGAL may predict a poor prognosis for glioma patients, the expression level increased with the increasing of WHO grade and 1p19q co-deletion status and IDH mutation status. The total methylation level and copy number variation of ITGAL were moderately correlated with its mRNA expression in LGG samples (P < 0.05). Furthermore, ITGAL was correlated with the immunosuppressive tumor microenvironment for the strong correlation with M2 macrophages and Tregs. Finally, GSEA showed the upregulation of ITGAL was mainly involved in the signal recognition and regulation between immune cells, and Toll-like receptor signaling pathway.
Conclusion
ITGAL is a novel tumor-related and immune-associated biomarker, which could predict the prognosis and effect of ICB therapy for glioma patients.
Bone marrow mesenchymal stem cells (BMSCs) can be differentiated into a variety of cells and repair damaged cells. We explore whether BMSCs can repair brain damage and synapses regeneration in mice under intrauterine ischemia and hypoxia. Twenty-five pregnant mice were assigned into
control group, 6% hypoxic injury group, 8% hypoxic injury group, 6% treatment group, 8% treatment group followed by analysis of the expression of MBP, MAG, CSPGs, IGF-1, NCAN, COLIV, SynD1G1, GFAP, GSK-3β, and β-actin by RT-PCR and Western blot. Our results showed that
the expression of MBP, MAG, COL IV, SynD1G1, IGF-1 in the treatment group were significantly higher than those in hypoxic injury group with significant differences between the 8% treatment group and 6% treatment group (P < 0.05). In conclusion, BMSCs can repair brain damage and synapse
regeneration in mice under different intrauterine ischemia and hypoxia conditions which might be through Wnt signaling pathway.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.